Immatics N.V. Ordinary Shares is a clinical-stage biopharmaceutical company focused on developing highly targeted immunotherapies for the treatment of solid tumors. With a proprietary platform that combines tumor-specific antigens and immune cell therapies, the company aims to improve outcomes for patients with cancer. Immatics’ pipeline includes multiple product candidates in various stages of development.
